Noninvasive strategies for metabolic dysfunction-associated steatotic liver disease assessment and referral in Japan

doi:10.3748/wjg.v32.i2.114097

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 2

This Article

(40)

(44)

(0)

(1)

(1883)

(2)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Evidence Review

World J Gastroenterol. Jan 14, 2026; 32(2): 114097
Published online Jan 14, 2026. doi: 10.3748/wjg.v32.i2.114097

Table 4 Cutoff scores in guidelines and clinical guidance for the enhanced liver fibrosis test

Guidelines/clinical guidance	Cutoffs for the ELF test
EASL-EASD-EASO Clinical Practice Guidelines[15]	Rule-out: 7.7
EASL-EASD-EASO Clinical Practice Guidelines[15]	Rule-in: 9.8
AASLD Practice Guidance[13]	Low risk: < 7.7
	Intermediate risk: 7.7-9.8
	High risk: > 9.8
ADA Guidelines[14]	Single cutoff: 9.8

ELF: Enhanced liver fibrosis; EASL: European Association for the Study of the Liver; EASD: European Association for the Study of Diabetes; EASO: European Association for the Study of Obesity; AASLD: American Association for the Study of Liver Disease; ADA: American Diabetes Association.

Full Size Table

Citation: Kamada Y, Sumida Y, Takahashi H, Ishiba H, Kawanaka M, Tada T, Yoneda M, Imajo K, Seko Y, Fujii H, Nakajima A. Noninvasive strategies for metabolic dysfunction-associated steatotic liver disease assessment and referral in Japan. World J Gastroenterol 2026; 32(2): 114097
URL: https://www.wjgnet.com/1007-9327/full/v32/i2/114097.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i2.114097

Kamada Y, Sumida Y, Takahashi H, Ishiba H, Kawanaka M, Tada T, Yoneda M, Imajo K, Seko Y, Fujii H, Nakajima A. Noninvasive strategies for metabolic dysfunction-associated steatotic liver disease assessment and referral in Japan. World J Gastroenterol 2026; 32(2): 114097 [PMID: 41551835 DOI: 10.3748/wjg.v32.i2.114097]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.